These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22027306)

  • 21. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.
    Gómez AM; Marín Carrillo LF; Muñoz Velandia OM; Rondón Sepúlveda MA; Arévalo Correa CM; Mora Garzón E; Cuervo Diaz MC; Henao Carrillo DC
    Diabetes Technol Ther; 2017 Feb; 19(2):109-114. PubMed ID: 28001445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT.
    Benhalima K; van Nes F; Laenen A; Gillard P; Mathieu C
    Diabetologia; 2021 Dec; 64(12):2725-2730. PubMed ID: 34647140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fear of hypoglycemia in children with type 1 diabetes and their parents: Effect of pump therapy and continuous glucose monitoring with option of low glucose suspend in the CGM TIME trial.
    Verbeeten KC; Perez Trejo ME; Tang K; Chan J; Courtney JM; Bradley BJ; McAssey K; Clarson C; Kirsch S; Curtis JR; Mahmud FH; Richardson C; Cooper T; Lawson ML;
    Pediatr Diabetes; 2021 Mar; 22(2):288-293. PubMed ID: 33179818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes.
    Ly TT; Brnabic AJ; Eggleston A; Kolivos A; McBride ME; Schrover R; Jones TW
    Value Health; 2014 Jul; 17(5):561-9. PubMed ID: 25128049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
    Choudhary P; de Portu S; Arrieta A; Castañeda J; Campbell FM
    Diabet Med; 2019 Sep; 36(9):1100-1108. PubMed ID: 31134668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
    Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
    Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
    Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
    Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Predictive Low Glucose Management System in Prevention of Clinically Significant Hypoglycemia in Type 1 Diabetes. A Preliminary Study Identifying the Most Common Events Leading Up to Hypoglycemia During Insulin Pump Therapy.
    Thomakos P; Mitrakou A; Kepaptsoglou O; Taraoune I; Barreto C; Zoupas CS
    Exp Clin Endocrinol Diabetes; 2021 May; 129(5):385-389. PubMed ID: 30986882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
    Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
    Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of Automated Insulin Suspension and Glucose Responses with the Predictive Low-Glucose Management System.
    Abraham MB; Smith GJ; Nicholas JA; Fairchild JM; King BR; Ambler GR; Cameron FJ; Davis EA; Jones TW;
    Diabetes Technol Ther; 2019 Jan; 21(1):28-34. PubMed ID: 30585769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark.
    Roze S; de Portu S; Smith-Palmer J; Delbaere A; Valentine W; Ridderstråle M
    Diabetes Res Clin Pract; 2017 Jun; 128():6-14. PubMed ID: 28432898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lower versus standard sucrose dose for treating hypoglycemia in patients with type 1 diabetes mellitus in therapy with predictive low glucose suspend (PLGS) augmented insulin pumps: A randomized crossover trial in Santiago, Chile.
    Grassi B; Onetto MT; Zapata Y; Jofré P; Echeverría G
    Diabetes Metab Syndr; 2021; 15(3):695-701. PubMed ID: 33813244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose Management.
    Choudhary P; Olsen BS; Conget I; Welsh JB; Vorrink L; Shin JJ
    Diabetes Technol Ther; 2016 May; 18(5):288-91. PubMed ID: 26907513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
    Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of real-life insulin pump with predictive low-glucose management use for 3 months: Analysis of the patients treated in a Japanese center.
    Tsunemi A; Sato J; Kurita M; Wakabayashi Y; Waseda N; Koshibu M; Shinohara M; Ozaki A; Nakamura H; Hirano N; Ikeda F; Satoh H; Watada H
    J Diabetes Investig; 2020 Nov; 11(6):1564-1569. PubMed ID: 32374513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of Insulin-Induced Hypoglycemia in Type 1 Diabetes with Predictive Low Glucose Management System.
    Abraham MB; de Bock M; Paramalingam N; O'Grady MJ; Ly TT; George C; Roy A; Spital G; Karula S; Heels K; Gebert R; Fairchild JM; King BR; Ambler GR; Cameron F; Davis EA; Jones TW
    Diabetes Technol Ther; 2016 Jul; 18(7):436-43. PubMed ID: 27148807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery.
    Weiss R; Garg SK; Bergenstal RM; Klonoff DC; Bode BW; Bailey TS; Thrasher J; Schwartz F; Welsh JB; Kaufman FR;
    J Diabetes Sci Technol; 2015 May; 9(5):1016-20. PubMed ID: 25986629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accuracy assessment of online glucose monitoring by a subcutaneous enzymatic glucose sensor during exercise in patients with type 1 diabetes treated by continuous subcutaneous insulin infusion.
    Radermecker RP; Fayolle C; Brun JF; Bringer J; Renard E
    Diabetes Metab; 2013 May; 39(3):258-62. PubMed ID: 23522730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.